Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials

By afschroeder • October 21, 2026

McInnes IB, Stein Gold L, Bissonnette R, Lebwohl MG, Reyes-Servin O, Cafone J, Yang YW, Chakravarty SD, Iaconangelo C, Li S, Shagroni T, Lozenski K, Armstrong AW, Merola JF. Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials. J Psoriasis Psoriatic Arthritis. 2026 Oct 18:24755303261494526. doi: 10.1177/24755303261494526. Epub ahead of print. PMID: 42898453; PMCID: PMC13677984.

Tags: Dermatology, icotrokinra, interleukin-23 inhibition, interleukin-23 receptor, oral peptide, patient-reported outcomes, plaque psoriasis, psoriatic arthritis, Publications

Initiating Biologics in Atopic Dermatitis: Global Practices and Recommendations from the AMAZE Project

Armstrong AW, Kim HJ, Pink AE, Gorelick J, Rossi M, Trzeciak M, Deleuran M, Nakajima S, Prajapati VH. Initiating Biologics in Atopic Dermatitis: Global Practices[...]

Reply to Botto et al’s “Applicant interview metrics and preference signaling in dermatology: A serial cross-sectional study”

Fleshner L, Chan R, Klufas T, Grant-Kels JM, Zhou AE. Reply to Botto et al's "Applicant interview metrics and preference signaling in dermatology: A serial[...]

Identification of a spatially organized TREM2-associated permissive macrophage niche in human pulmonary tuberculosis alveolar pneumonia

Teles RMB, Benabdessalem C, Perrie J, Wei C, West J, de Andrade Silva BJ, Andrade PR, Mansky LA, Divaka P, Fischbacher L, Lam K, Ma[...]